ASP Isotopes (ASPI) investor relations material

Helium market and supply crisis

• Helium supply is highly concentrated and irreplaceable, with recurring global shortages over the past 20 years.

• Current disruptions, including damage at Qatar's Ras Laffan and Strait of Hormuz closure, have taken 25%-30% of global supply offline, leading to rationing.

• Renergen's South African reserves offer uniquely high helium concentrations, with phase I of production ahead of schedule and phase II to begin by year-end.

• Phase I targets $20M annual revenue and $5M gross profit; phase II could reach $295M revenue and $230M gross profit at current prices.

• U.S. government has committed $0.5B to phase II, recognizing the facility as critical to national security.

Isotope production and commercialization

• Silicon-28: First samples shipped in 2023, with plant upgrades underway; first commercial shipments expected imminently.

• Carbon-14: Feedstock arriving soon, with production to start within 60-90 days; take-or-pay contract in place for $2.5M-$5M annually.

• Ytterbium-176: Plant operational after laser repair, with commercial volumes expected in H1 2026.

• All three isotopes expected to generate commercial revenue by H1 2026.

Regulatory and commercial milestones

• Service agreement with Necsa enables uranium enrichment at South Africa's Pelindaba site, leveraging existing licenses.

• MOU signed with a major U.S. customer to expand uranium enrichment in the U.S.

• Partnership with TerraPower supports advanced reactor fuel supply, with close collaboration and regular updates.